https://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&feed=atom&action=historyBCG Vaccine - Revision history2024-03-29T14:59:35ZRevision history for this page on the wikiMediaWiki 1.39.6https://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=95002&oldid=prevTreimans: /* Tuberculosis Function */2013-12-14T20:26:12Z<p><span dir="auto"><span class="autocomment">Tuberculosis Function</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 20:26, 14 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Tuberculosis Function==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Tuberculosis Function==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Tuberculosis is almost always contracted through the air when the respiratory system ingests the bacteria <i>Mycobacterium tuberculosis</i>. Once the bacteria enter the organism, <i>Mycobacterium tuberculosis</i> becomes implanted in alveoli and is usually ingested by nearby macrophages, although it can also be ingested by alveolar epithelial type II pneumocytes (4). When the bacteria enter the macrophage it is phagocytosed by macrophage mannose and occupies an endocytic vacuole called the phagosome (4). After the <i>Mycobacterium tuberculosis</i> becomes assimilated in the phagosome, it must avoid death from the macrophage’s phagolysosome. <i>Mycobacterium tuberculosis</i> has many mechanisms to combat this problem, which include stopping phagosome-lysosome fusion and recruiting RAB proteins to prevent phagosomal maturation and catalyze endosome trafficking (4). If the bacteria continue to grow in the lung, it can have varying effects depending on the strength of the organism’s immune system. Latent tuberculosis occurs when the organism has a strong immune system; in which case the infection cannot progress and remains dormant. However, if an organism has a weak immune system, the granulomatous focal lesions that prohibit the spread of bacteria liquefy and allow <i>Mycobacterium tuberculosis</i> to replicate and spread throughout the lungs (4). It is for this reason that other factors that slow the immune system such as HIV, sickness, and aging can bolster the effectiveness of <i>Mycobacterium tuberculosis</i>. Eventually, uncontrolled growth of Mycobacterium tuberculosis can lead to lung damage and eventually suffocation and death because of oxygen deprivation (4).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Tuberculosis is almost always contracted through the air when the respiratory system ingests the bacteria <i>Mycobacterium tuberculosis</i>. Once the bacteria enter the organism, <i>Mycobacterium tuberculosis</i> becomes implanted in alveoli and is usually ingested by nearby macrophages, although it can also be ingested by alveolar epithelial type II pneumocytes (4). When the bacteria enter the macrophage it is phagocytosed by macrophage mannose and occupies an endocytic vacuole called the phagosome (4). After the <i>Mycobacterium tuberculosis</i> becomes assimilated in the phagosome, it must avoid death from the macrophage’s phagolysosome. <i>Mycobacterium tuberculosis</i> has many mechanisms to combat this problem, which include stopping phagosome-lysosome fusion and recruiting RAB proteins to prevent phagosomal maturation and catalyze endosome trafficking (4). If the bacteria continue to grow in the lung, it can have varying effects depending on the strength of the organism’s immune system. Latent tuberculosis occurs when the organism has a strong immune system; in which case the infection cannot progress and remains dormant. However, if an organism has a weak immune system, the granulomatous focal lesions that prohibit the spread of bacteria liquefy and allow <i>Mycobacterium tuberculosis</i> to replicate and spread throughout the lungs (4). It is for this reason that other factors that slow the immune system such as HIV, sickness, and aging can bolster the effectiveness of <i>Mycobacterium tuberculosis</i>. Eventually, uncontrolled growth of <ins style="font-weight: bold; text-decoration: none;">''</ins>Mycobacterium tuberculosis<ins style="font-weight: bold; text-decoration: none;">'' </ins>can lead to lung damage and eventually suffocation and death because of oxygen deprivation (4).</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:BCG Cycle Picture.jpg|360 px|thumb|left|Figure 2. A diagram that shows how CD 4 T cells stop <i>Mycobacterium tuberculosis</i>. Image: Molecular Medicine Today. http://www.sciencedirect.com/science/article/pii/S1357431099015944]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:BCG Cycle Picture.jpg|360 px|thumb|left|Figure 2. A diagram that shows how CD 4 T cells stop <i>Mycobacterium tuberculosis</i>. Image: Molecular Medicine Today. http://www.sciencedirect.com/science/article/pii/S1357431099015944]]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=95001&oldid=prevTreimans: /* Structural and Functional Differences of Mycobacterium tuberculosis and BCG */2013-12-14T20:25:36Z<p><span dir="auto"><span class="autocomment">Structural and Functional Differences of Mycobacterium tuberculosis and BCG</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 20:25, 14 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l17">Line 17:</td>
<td colspan="2" class="diff-lineno">Line 17:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>The <i>Mycobacterium bovis</i> strain of the BCG vaccine is similar to <i>Mycobacterium tuberculosis</i>, but there are some structural and functional differences between the two strains. Recent genetic sequencing has shown that the BCG vaccine and <i>Mycobacterium tuberculosis</i> have three distinct genomic regions (2). The first genomic difference, named RD 3, is a 9.3-kb genomic segment that is absent in BCG compared to virulent <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> (2). However, researchers concluded that the absence of RD3 occurred during the derivation of BCG and that RD3 did not make <i>Mycobacterium tuberculosis</i> virulent. A similar conclusion was made for the genomic segment RD2, which also disappeared from the BCG strain after it had already been used as a vaccine. However, researchers discovered through two-dimensional gel electrophoresis that RD1 (Figure 3), a 9.5-kb DNA segment absent in BCG, could have significant implications as to why BCG is not virulent for humans. RD1 was found to repress at least ten proteins involved the in the regulation of multiple genetic loci which suggests that it is likely that a regulatory mutation is responsible for the lack of virulence in BCG (2). </div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>The <i>Mycobacterium bovis</i> strain of the BCG vaccine is similar to <i>Mycobacterium tuberculosis</i>, but there are some structural and functional differences between the two strains. Recent genetic sequencing has shown that the BCG vaccine and <i>Mycobacterium tuberculosis</i> have three distinct genomic regions (2). The first genomic difference, named RD 3, is a 9.3-kb genomic segment that is absent in BCG compared to virulent <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> (2). However, researchers concluded that the absence of RD3 occurred during the derivation of BCG and that RD3 did not make <i>Mycobacterium tuberculosis</i> virulent. A similar conclusion was made for the genomic segment RD2, which also disappeared from the BCG strain after it had already been used as a vaccine. However, researchers discovered through two-dimensional gel electrophoresis that RD1 (Figure 3), a 9.5-kb DNA segment absent in BCG, could have significant implications as to why BCG is not virulent for humans. RD1 was found to repress at least ten proteins involved the in the regulation of multiple genetic loci which suggests that it is likely that a regulatory mutation is responsible for the lack of virulence in BCG (2). </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Some researchers now hypothesize that the absence of RD1 calls for BCG-derived antigens to the vacuolar pathway to antigen presentation (5). Additionally, another study injected mice with a mutated <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> strain that did not contain RD1 and found more ways in which the presence of BCG differentiates itself from Mycobacterium tuberculosis. The mutant mice could not cause cytolysis of pneumocytes compared to their infected counterparts (7). They found that RD1 codes for the protein ESAT 6, which mediates cytolysis of the infected cell and tissue invasiveness (7). Since BCG lacks RD1, cytolysis does not occur and the organism can remain unharmed.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Some researchers now hypothesize that the absence of RD1 calls for BCG-derived antigens to the vacuolar pathway to antigen presentation (5). Additionally, another study injected mice with a mutated <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> strain that did not contain RD1 and found more ways in which the presence of BCG differentiates itself from <ins style="font-weight: bold; text-decoration: none;"><i></ins>Mycobacterium tuberculosis<ins style="font-weight: bold; text-decoration: none;"></i></ins>. The mutant mice could not cause cytolysis of pneumocytes compared to their infected counterparts (7). They found that RD1 codes for the protein ESAT 6, which mediates cytolysis of the infected cell and tissue invasiveness (7). Since BCG lacks RD1, cytolysis does not occur and the organism can remain unharmed.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Problems with BCG==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Problems with BCG==</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=95000&oldid=prevTreimans: /* Tuberculosis Function */2013-12-14T20:22:23Z<p><span dir="auto"><span class="autocomment">Tuberculosis Function</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 20:22, 14 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Tuberculosis Function==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Tuberculosis Function==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Tuberculosis is almost always contracted through the air when the respiratory system ingests the bacteria <i>Mycobacterium <del style="font-weight: bold; text-decoration: none;">Tuberculosis</del></i>. Once the bacteria enter the organism, <i>Mycobacterium tuberculosis</i> becomes implanted in alveoli and is usually ingested by nearby macrophages, although it can also be ingested by alveolar epithelial type II pneumocytes (4). When the bacteria enter the macrophage it is phagocytosed by macrophage mannose and occupies an endocytic vacuole called the phagosome (4). After the <i>Mycobacterium tuberculosis</i> becomes assimilated in the phagosome, it must avoid death from the macrophage’s phagolysosome. <i>Mycobacterium tuberculosis</i> has many mechanisms to combat this problem, which include stopping phagosome-lysosome fusion and recruiting RAB proteins to prevent phagosomal maturation and catalyze endosome trafficking (4). If the bacteria continue to grow in the lung, it can have varying effects depending on the strength of the organism’s immune system. Latent tuberculosis occurs when the organism has a strong immune system; in which case the infection cannot progress and remains dormant. However, if an organism has a weak immune system, the granulomatous focal lesions that prohibit the spread of bacteria liquefy and allow <i>Mycobacterium tuberculosis</i> to replicate and spread throughout the lungs (4). It is for this reason that other factors that slow the immune system such as HIV, sickness, and aging can bolster the effectiveness of <i>Mycobacterium tuberculosis</i>. Eventually, uncontrolled growth of Mycobacterium tuberculosis can lead to lung damage and eventually suffocation and death because of oxygen deprivation (4).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Tuberculosis is almost always contracted through the air when the respiratory system ingests the bacteria <i>Mycobacterium <ins style="font-weight: bold; text-decoration: none;">tuberculosis</ins></i>. Once the bacteria enter the organism, <i>Mycobacterium tuberculosis</i> becomes implanted in alveoli and is usually ingested by nearby macrophages, although it can also be ingested by alveolar epithelial type II pneumocytes (4). When the bacteria enter the macrophage it is phagocytosed by macrophage mannose and occupies an endocytic vacuole called the phagosome (4). After the <i>Mycobacterium tuberculosis</i> becomes assimilated in the phagosome, it must avoid death from the macrophage’s phagolysosome. <i>Mycobacterium tuberculosis</i> has many mechanisms to combat this problem, which include stopping phagosome-lysosome fusion and recruiting RAB proteins to prevent phagosomal maturation and catalyze endosome trafficking (4). If the bacteria continue to grow in the lung, it can have varying effects depending on the strength of the organism’s immune system. Latent tuberculosis occurs when the organism has a strong immune system; in which case the infection cannot progress and remains dormant. However, if an organism has a weak immune system, the granulomatous focal lesions that prohibit the spread of bacteria liquefy and allow <i>Mycobacterium tuberculosis</i> to replicate and spread throughout the lungs (4). It is for this reason that other factors that slow the immune system such as HIV, sickness, and aging can bolster the effectiveness of <i>Mycobacterium tuberculosis</i>. Eventually, uncontrolled growth of Mycobacterium tuberculosis can lead to lung damage and eventually suffocation and death because of oxygen deprivation (4).</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:BCG Cycle Picture.jpg|360 px|thumb|left|Figure 2. A diagram that shows how CD 4 T cells stop <i>Mycobacterium tuberculosis</i>. Image: Molecular Medicine Today. http://www.sciencedirect.com/science/article/pii/S1357431099015944]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:BCG Cycle Picture.jpg|360 px|thumb|left|Figure 2. A diagram that shows how CD 4 T cells stop <i>Mycobacterium tuberculosis</i>. Image: Molecular Medicine Today. http://www.sciencedirect.com/science/article/pii/S1357431099015944]]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94790&oldid=prevTreimans: /* Conclusion and Potential New Treatments */2013-12-06T04:44:24Z<p><span dir="auto"><span class="autocomment">Conclusion and Potential New Treatments</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:44, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l23">Line 23:</td>
<td colspan="2" class="diff-lineno">Line 23:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Conclusion and Potential New Treatments==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Conclusion and Potential New Treatments==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Researchers are currently looking for ways to improve the efficacy of the BCG vaccine as well as looking at alternative methods for a vaccine against tuberculosis. One method used by researchers involves increasing the expression of immunodominant genes and adding deleted genes back to BCG since it is hypothesized that BCG has lost effectiveness over time because of gene loss (8). Another approach under testing involves strengthening the body’s immune response by maximizing the antigen export from BCG (8). Researchers are currently testing a vaccine strain that is unable to arrest phagosome maturation and expresses genes thought to weaken the phagosome membrane (8). If the membrane is weakened, than CD8 T cells might have more access to bacterial-derived antigens from cytosolic scavenger pathways (8). These are only two of many strategies currently being tested by researchers in an effort to combat <i>Mycobacterium tuberculosis</i>. Researchers have been and continue to extensively search for a better vaccine to fight <i>Mycobacterium tuberculosis</i>, but as of today BCG, even with its varied effectiveness, remains the safest and most widely used option.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Researchers are currently looking for ways to improve the efficacy of the BCG vaccine as well as looking at alternative methods for a vaccine against tuberculosis. One method used by researchers involves increasing the expression of immunodominant genes and adding deleted genes back to BCG since it is hypothesized that BCG has lost effectiveness over time because of gene loss (8). Another approach under testing involves strengthening the body’s immune response by maximizing the antigen export from BCG (8). Researchers are currently testing a vaccine strain that is unable to arrest phagosome maturation and expresses genes thought to weaken the phagosome membrane (8). If the membrane is weakened, than CD8 T cells might have more access to bacterial-derived antigens from cytosolic scavenger pathways (8). These are only two of many strategies currently being tested by researchers in an effort to combat <i>Mycobacterium tuberculosis</i>. Researchers have been and continue to extensively search for a better vaccine to fight <i>Mycobacterium tuberculosis</i>, but as of today<ins style="font-weight: bold; text-decoration: none;">, </ins>BCG, even with its varied effectiveness, remains the safest and most widely used option.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94788&oldid=prevTreimans: /* Problems with BCG */2013-12-06T04:42:20Z<p><span dir="auto"><span class="autocomment">Problems with BCG</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:42, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l20">Line 20:</td>
<td colspan="2" class="diff-lineno">Line 20:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Problems with BCG==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Problems with BCG==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Although BCG vaccinations have helped millions of people, the effectiveness of the vaccine <del style="font-weight: bold; text-decoration: none;">is still of great variance</del>. One major reason for BCG’s varying efficacy is due to the vast amount of different BCG strains. When BCG was first distributed around the world in 1924, several different distinct daughter strains developed because BCG is a live vaccine (1). As early as the 1950s, scientists realized BCG substrains contained unique biochemical and immunological phenotypes. Researchers have now discovered that different strains vary in the amount of protein antigens which affect the immunogenicity of current BCG strains (1). One example of the vast differences in BCG strains can be seen through examination of phthiocerol dimycocerosates (PDIMs) and phenolic glycolipids (PGLs). Both molecules play an important role in modulation of the immune response, and dysfunctional PDIMs and PGLs can lead to increased attenuated virulence (1). Many of the strains contain variations of PDIMs and PGLs due to mutations; therefore, different BCG strains have varied effectiveness because of their unique biochemical characteristics.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Although BCG vaccinations have helped millions of people, the effectiveness of the vaccine <ins style="font-weight: bold; text-decoration: none;">greatly varies</ins>. One major reason for BCG’s varying efficacy is due to the vast amount of different BCG strains. When BCG was first distributed around the world in 1924, several different distinct daughter strains developed because BCG is a live vaccine (1). As early as the 1950s, scientists realized BCG substrains contained unique biochemical and immunological phenotypes. Researchers have now discovered that different strains vary in the amount of protein antigens which affect the immunogenicity of current BCG strains (1). One example of the vast differences in BCG strains can be seen through examination of phthiocerol dimycocerosates (PDIMs) and phenolic glycolipids (PGLs). Both molecules play an important role in modulation of the immune response, and dysfunctional PDIMs and PGLs can lead to increased attenuated virulence (1). Many of the strains contain variations of PDIMs and PGLs due to mutations; therefore, different BCG strains have varied effectiveness because of their unique biochemical characteristics.</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Conclusion and Potential New Treatments==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Conclusion and Potential New Treatments==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Researchers are currently looking for ways to improve the efficacy of the BCG vaccine as well as looking at alternative methods for a vaccine against tuberculosis. One method used by researchers involves increasing the expression of immunodominant genes and adding deleted genes back to BCG since it is hypothesized that BCG has lost effectiveness over time because of gene loss (8). Another approach under testing involves strengthening the body’s immune response by maximizing the antigen export from BCG (8). Researchers are currently testing a vaccine strain that is unable to arrest phagosome maturation and expresses genes thought to weaken the phagosome membrane (8). If the membrane is weakened, than CD8 T cells might have more access to bacterial-derived antigens from cytosolic scavenger pathways (8). These are only two of many strategies currently being tested by researchers in an effort to combat <i>Mycobacterium tuberculosis</i>. Researchers have been and continue to extensively search for a better vaccine to fight <i>Mycobacterium tuberculosis</i>, but as of today BCG, even with its varied effectiveness, remains the safest and most widely used option.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Researchers are currently looking for ways to improve the efficacy of the BCG vaccine as well as looking at alternative methods for a vaccine against tuberculosis. One method used by researchers involves increasing the expression of immunodominant genes and adding deleted genes back to BCG since it is hypothesized that BCG has lost effectiveness over time because of gene loss (8). Another approach under testing involves strengthening the body’s immune response by maximizing the antigen export from BCG (8). Researchers are currently testing a vaccine strain that is unable to arrest phagosome maturation and expresses genes thought to weaken the phagosome membrane (8). If the membrane is weakened, than CD8 T cells might have more access to bacterial-derived antigens from cytosolic scavenger pathways (8). These are only two of many strategies currently being tested by researchers in an effort to combat <i>Mycobacterium tuberculosis</i>. Researchers have been and continue to extensively search for a better vaccine to fight <i>Mycobacterium tuberculosis</i>, but as of today BCG, even with its varied effectiveness, remains the safest and most widely used option.</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94785&oldid=prevTreimans: /* Structural and Functional Differences of Mycobacterium tuberculosis and BCG */2013-12-06T04:39:58Z<p><span dir="auto"><span class="autocomment">Structural and Functional Differences of Mycobacterium tuberculosis and BCG</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:39, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l15">Line 15:</td>
<td colspan="2" class="diff-lineno">Line 15:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Structural and Functional Differences of <i>Mycobacterium tuberculosis</i> and BCG==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Structural and Functional Differences of <i>Mycobacterium tuberculosis</i> and BCG==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:RD1.jpg|400 px|thumb|right|Figure 3. Gene Composition and Function of RD1. Image:2003 Nature Publishing Group. http://www.pasteur.fr/recherche/unites/Pmi/Young.pdf]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:RD1.jpg|400 px|thumb|right|Figure 3. Gene Composition and Function of RD1. Image:2003 Nature Publishing Group. http://www.pasteur.fr/recherche/unites/Pmi/Young.pdf]]</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The <i>Mycobacterium bovis</i> strain of the BCG vaccine is similar to <i>Mycobacterium tuberculosis</i>, but there are some structural and functional differences between the two strains. Recent genetic sequencing has shown that the BCG vaccine and <i>Mycobacterium tuberculosis</i> have three distinct genomic regions (2). The first genomic difference, named RD 3, is a 9.3-kb genomic segment that is absent in BCG compared to virulent <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> (2). However, researchers concluded that the absence of RD3 occurred during the derivation of BCG and that RD3 did not make <i>Mycobacterium tuberculosis</i> virulent. A similar conclusion was made for the genomic segment RD2, which also disappeared from the BCG strain after it had already been used as a vaccine. However, <del style="font-weight: bold; text-decoration: none;">the </del>researchers discovered through two-dimensional gel electrophoresis that RD1 (Figure 3), a 9.5-kb DNA segment absent in BCG, could have significant implications as to why BCG is not virulent for humans. RD1 was found to repress at least ten proteins involved the in the regulation of multiple genetic loci which suggests that it is likely that a regulatory mutation is responsible for the lack of virulence in BCG (2). </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>The <i>Mycobacterium bovis</i> strain of the BCG vaccine is similar to <i>Mycobacterium tuberculosis</i>, but there are some structural and functional differences between the two strains. Recent genetic sequencing has shown that the BCG vaccine and <i>Mycobacterium tuberculosis</i> have three distinct genomic regions (2). The first genomic difference, named RD 3, is a 9.3-kb genomic segment that is absent in BCG compared to virulent <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> (2). However, researchers concluded that the absence of RD3 occurred during the derivation of BCG and that RD3 did not make <i>Mycobacterium tuberculosis</i> virulent. A similar conclusion was made for the genomic segment RD2, which also disappeared from the BCG strain after it had already been used as a vaccine. However, researchers discovered through two-dimensional gel electrophoresis that RD1 (Figure 3), a 9.5-kb DNA segment absent in BCG, could have significant implications as to why BCG is not virulent for humans. RD1 was found to repress at least ten proteins involved the in the regulation of multiple genetic loci which suggests that it is likely that a regulatory mutation is responsible for the lack of virulence in BCG (2). </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Some researchers now hypothesize that the absence of RD1 calls for BCG-derived antigens to the vacuolar pathway to antigen presentation (5). Additionally, another study injected mice with a mutated <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> strain that did not contain RD1 and found more ways in which the presence of BCG differentiates itself from Mycobacterium tuberculosis. The mutant mice could not cause cytolysis of pneumocytes compared to their infected counterparts (7). They found that RD1 codes for the protein ESAT 6, which mediates cytolysis of the infected cell and tissue invasiveness (7). Since BCG lacks RD1, cytolysis does not occur and the organism can remain unharmed.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Some researchers now hypothesize that the absence of RD1 calls for BCG-derived antigens to the vacuolar pathway to antigen presentation (5). Additionally, another study injected mice with a mutated <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> strain that did not contain RD1 and found more ways in which the presence of BCG differentiates itself from Mycobacterium tuberculosis. The mutant mice could not cause cytolysis of pneumocytes compared to their infected counterparts (7). They found that RD1 codes for the protein ESAT 6, which mediates cytolysis of the infected cell and tissue invasiveness (7). Since BCG lacks RD1, cytolysis does not occur and the organism can remain unharmed.</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94783&oldid=prevTreimans: /* Structural and Functional Differences of Mycobacterium tuberculosis and BCG */2013-12-06T04:39:09Z<p><span dir="auto"><span class="autocomment">Structural and Functional Differences of Mycobacterium tuberculosis and BCG</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:39, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l15">Line 15:</td>
<td colspan="2" class="diff-lineno">Line 15:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Structural and Functional Differences of <i>Mycobacterium tuberculosis</i> and BCG==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Structural and Functional Differences of <i>Mycobacterium tuberculosis</i> and BCG==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:RD1.jpg|400 px|thumb|right|Figure 3. Gene Composition and Function of RD1. Image:2003 Nature Publishing Group. http://www.pasteur.fr/recherche/unites/Pmi/Young.pdf]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:RD1.jpg|400 px|thumb|right|Figure 3. Gene Composition and Function of RD1. Image:2003 Nature Publishing Group. http://www.pasteur.fr/recherche/unites/Pmi/Young.pdf]]</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The <i>Mycobacterium bovis</i> strain of the BCG vaccine is similar to <i>Mycobacterium tuberculosis</i>, but there are some structural and functional differences between the two strains. Recent genetic sequencing has shown that the BCG vaccine and <i>Mycobacterium tuberculosis</i> have three distinct genomic regions (2). The first genomic difference, named RD 3, is a 9.3-kb genomic segment that is absent in BCG compared to virulent <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> (2). However, <del style="font-weight: bold; text-decoration: none;">the </del>researchers concluded that the absence of RD3 occurred during the derivation of BCG and that RD3 did not make <i>Mycobacterium tuberculosis</i> virulent. A similar conclusion was made for the genomic segment RD2, which also disappeared from the BCG strain after it had already been used as a vaccine. However, the researchers discovered through two-dimensional gel electrophoresis that RD1 (Figure 3), a 9.5-kb DNA segment absent in BCG, could have significant implications as to why BCG is not virulent for humans. RD1 was found to repress at least ten proteins involved the in the regulation of multiple genetic loci which suggests that it is likely that a regulatory mutation is responsible for the lack of virulence in BCG (2). </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>The <i>Mycobacterium bovis</i> strain of the BCG vaccine is similar to <i>Mycobacterium tuberculosis</i>, but there are some structural and functional differences between the two strains. Recent genetic sequencing has shown that the BCG vaccine and <i>Mycobacterium tuberculosis</i> have three distinct genomic regions (2). The first genomic difference, named RD 3, is a 9.3-kb genomic segment that is absent in BCG compared to virulent <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> (2). However, researchers concluded that the absence of RD3 occurred during the derivation of BCG and that RD3 did not make <i>Mycobacterium tuberculosis</i> virulent. A similar conclusion was made for the genomic segment RD2, which also disappeared from the BCG strain after it had already been used as a vaccine. However, the researchers discovered through two-dimensional gel electrophoresis that RD1 (Figure 3), a 9.5-kb DNA segment absent in BCG, could have significant implications as to why BCG is not virulent for humans. RD1 was found to repress at least ten proteins involved the in the regulation of multiple genetic loci which suggests that it is likely that a regulatory mutation is responsible for the lack of virulence in BCG (2). </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Some researchers now hypothesize that the absence of RD1 calls for BCG-derived antigens to the vacuolar pathway to antigen presentation (5). Additionally, another study injected mice with a mutated <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> strain that did not contain RD1 and found more ways in which the presence of BCG differentiates itself from Mycobacterium tuberculosis. The mutant mice could not cause cytolysis of pneumocytes compared to their infected counterparts (7). They found that RD1 codes for the protein ESAT 6, which mediates cytolysis of the infected cell and tissue invasiveness (7). Since BCG lacks RD1, cytolysis does not occur and the organism can remain unharmed.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>Some researchers now hypothesize that the absence of RD1 calls for BCG-derived antigens to the vacuolar pathway to antigen presentation (5). Additionally, another study injected mice with a mutated <i>Mycobacterium bovis</i> and <i>Mycobacterium tuberculosis</i> strain that did not contain RD1 and found more ways in which the presence of BCG differentiates itself from Mycobacterium tuberculosis. The mutant mice could not cause cytolysis of pneumocytes compared to their infected counterparts (7). They found that RD1 codes for the protein ESAT 6, which mediates cytolysis of the infected cell and tissue invasiveness (7). Since BCG lacks RD1, cytolysis does not occur and the organism can remain unharmed.</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94782&oldid=prevTreimans: /* BCG'S response to Mycobacterium tuberculosis */2013-12-06T04:38:22Z<p><span dir="auto"><span class="autocomment">BCG'S response to Mycobacterium tuberculosis</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:38, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l11">Line 11:</td>
<td colspan="2" class="diff-lineno">Line 11:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==BCG'S response to ''Mycobacterium tuberculosis''==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==BCG'S response to ''Mycobacterium tuberculosis''==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>BCG, like most vaccines, stimulates antibodies and creates a resistance without damaging the organism. The BCG vaccine recruits CD4 and CD8 T cells as a response to protective mycobacterial antigens (Figure 2) (5). After recruiting these cells, the new cells are exposed to the macrophage product interleukin 12 which calls for T <del style="font-weight: bold; text-decoration: none;">cell </del>to secrete interferon y (6). When <i>Mycobacterium tuberculosis</i> enters the cell, interferon y reduces the pH in the phagosomal membrane and produces superoxide and nitric oxide, which can destroy <i>Mycobacterium tuberculosis</i> (6).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>BCG, like most vaccines, stimulates antibodies and creates a resistance without damaging the organism. The BCG vaccine recruits CD4 and CD8 T cells as a response to protective mycobacterial antigens (Figure 2) (5). After recruiting these cells, the new cells are exposed to the macrophage product interleukin 12 which calls for T <ins style="font-weight: bold; text-decoration: none;">cells </ins>to secrete interferon y (6). When <i>Mycobacterium tuberculosis</i> enters the cell, interferon y reduces the pH in the phagosomal membrane and produces superoxide and nitric oxide, which can destroy <i>Mycobacterium tuberculosis</i> (6).</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Structural and Functional Differences of <i>Mycobacterium tuberculosis</i> and BCG==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Structural and Functional Differences of <i>Mycobacterium tuberculosis</i> and BCG==</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94774&oldid=prevTreimans: /* Introduction */2013-12-06T04:34:27Z<p><span dir="auto"><span class="autocomment">Introduction</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:34, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Introduction==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Introduction==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:120126-dendritic-cell-bcg-iah-300.jpg|thumb|300px|right|Figure 1. Image of a dendritic cell after ingesting a small amount of the BCG vaccine. Image: Institute for Animal Health http://www.bbsrc.ac.uk/news/health/2012/120126-pr-how-to-make-better-vaccines.aspx]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:120126-dendritic-cell-bcg-iah-300.jpg|thumb|300px|right|Figure 1. Image of a dendritic cell after ingesting a small amount of the BCG vaccine. Image: Institute for Animal Health http://www.bbsrc.ac.uk/news/health/2012/120126-pr-how-to-make-better-vaccines.aspx]]</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Bacille Calmette Guerin (BCG) is the most common vaccine administered to combat tuberculosis disease in the world. (1) The vaccine contains a weakened live strain of <i>Mycobacterium bovis</i>, which is present in cows and shares a common ancestor with the human tubercule bacillus <i>Mycobacterium tuberculosis</i> (2). Similar to other vaccines, BCG triggers the formation of antibodies from the harmless strain of <i>Myobacterium bovis</i> to help prevent tuberculosis (Figure 1)(1). The efficacy of BCG vaccine varies from 0-80% depending on age, the type of BCG vaccine, and the population (1). Although BCG remains as the primary vaccine against tuberculosis, it has only produced variable amounts of success. Many factors, including recent findings that distinct BCG strains have very different biochemical characteristics due to mutations, have further complicated the issue (1). Researchers are currently searching for a more effective way to treat tuberculosis disease, but none <del style="font-weight: bold; text-decoration: none;">has </del>been found to date (1).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Bacille Calmette Guerin (BCG) is the most common vaccine administered to combat tuberculosis disease in the world. (1) The vaccine contains a weakened live strain of <i>Mycobacterium bovis</i>, which is present in cows and shares a common ancestor with the human tubercule bacillus <i>Mycobacterium tuberculosis</i> (2). Similar to other vaccines, BCG triggers the formation of antibodies from the harmless strain of <i>Myobacterium bovis</i> to help prevent tuberculosis (Figure 1)(1). The efficacy of BCG vaccine varies from 0-80% depending on age, the type of BCG vaccine, and the population (1). Although BCG remains as the primary vaccine against tuberculosis, it has only produced variable amounts of success. Many factors, including recent findings that distinct BCG strains have very different biochemical characteristics due to mutations, have further complicated the issue (1). Researchers are currently searching for a more effective way to treat tuberculosis disease, but none <ins style="font-weight: bold; text-decoration: none;">have </ins>been found to date (1).</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Origin==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Origin==</div></td></tr>
</table>Treimanshttps://microbewiki.kenyon.edu/index.php?title=BCG_Vaccine&diff=94772&oldid=prevTreimans: /* Introduction */2013-12-06T04:33:37Z<p><span dir="auto"><span class="autocomment">Introduction</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:33, 6 December 2013</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Introduction==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Introduction==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:120126-dendritic-cell-bcg-iah-300.jpg|thumb|300px|right|Figure 1. Image of a dendritic cell after ingesting a small amount of the BCG vaccine. Image: Institute for Animal Health http://www.bbsrc.ac.uk/news/health/2012/120126-pr-how-to-make-better-vaccines.aspx]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Image:120126-dendritic-cell-bcg-iah-300.jpg|thumb|300px|right|Figure 1. Image of a dendritic cell after ingesting a small amount of the BCG vaccine. Image: Institute for Animal Health http://www.bbsrc.ac.uk/news/health/2012/120126-pr-how-to-make-better-vaccines.aspx]]</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Bacille Calmette Guerin (BCG) is the most common vaccine administered to combat tuberculosis disease in the world. (1) The vaccine contains a weakened live strain of <i>Mycobacterium bovis</i>, which is present in cows and shares a common ancestor with the human tubercule bacillus <i>Mycobacterium tuberculosis</i> (2). Similar to other vaccines, BCG triggers the formation of antibodies from the harmless strain of <i>Myobacterium bovis</i> to help prevent tuberculosis (Figure 1)<del style="font-weight: bold; text-decoration: none;">, and the vaccine usually leaves a skin lesion or a scar </del>(1). The efficacy of BCG vaccine varies from 0-80% depending on age, the type of BCG vaccine, and the population (1). Although BCG remains as the primary vaccine against tuberculosis, it has only produced variable amounts of success. Many factors, including recent findings that distinct BCG strains have very different biochemical characteristics due to mutations, have further complicated the issue (1). Researchers are currently searching for a more effective way to treat tuberculosis disease, but none has been found to date (1).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Bacille Calmette Guerin (BCG) is the most common vaccine administered to combat tuberculosis disease in the world. (1) The vaccine contains a weakened live strain of <i>Mycobacterium bovis</i>, which is present in cows and shares a common ancestor with the human tubercule bacillus <i>Mycobacterium tuberculosis</i> (2). Similar to other vaccines, BCG triggers the formation of antibodies from the harmless strain of <i>Myobacterium bovis</i> to help prevent tuberculosis (Figure 1)(1). The efficacy of BCG vaccine varies from 0-80% depending on age, the type of BCG vaccine, and the population (1). Although BCG remains as the primary vaccine against tuberculosis, it has only produced variable amounts of success. Many factors, including recent findings that distinct BCG strains have very different biochemical characteristics due to mutations, have further complicated the issue (1). Researchers are currently searching for a more effective way to treat tuberculosis disease, but none has been found to date (1).</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Origin==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Origin==</div></td></tr>
</table>Treimans